U.S. Stock Market Midday Update: Cibus stock price plummets 11.14%, market sentiment is low, and increased volatility raises concerns

U.S. Stock Market Midday Update Cibus fell 11.14%. Cibus fell 11.14%. There have been no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news Stocks with High Trading Volume in the Industry AbbVie rose 0.28%. Based on recent news, On January 21, analyst Bernstein maintained a hold rating on AbbVie and set a target price of $225. Although the analyst's rating on AbbVie remains unchanged, market confidence in its future performance has increased, driving the stock price up. On January 21, AbbVie's technology route in the self-immune ADC field is considered to have the potential for sustained deep relief. Differentiated competition within the industry is beginning to emerge, and AbbVie's technology route is viewed positively by the market, further boosting the stock price. On January 20, MarketBeat's analysis showed that although AbbVie is currently rated as a moderate buy, top analysts believe there are other stocks that are more worthy of purchase. This news had a somewhat negative impact on AbbVie's stock price, but overall market sentiment remains positive. Competition in the self-immune ADC field is intensifying, and market sentiment is optimistic. Amgen rose 2.34%. Based on recent key news: On January 21, Bernstein downgraded Amgen's rating to market perform, believing that 2026 may be a year of waiting, with the stock price fluctuating around the target of $335. This rating adjustment may affect investor confidence, leading to stock price volatility. On January 20, Piper Sandler analyst David Amsellem reiterated a buy rating on Amgen and set a target price of $381. This positive rating may boost market optimism towards Amgen, driving the stock price up. On January 20, Amgen's GLP-1 drug MariTide entered phase three research, covering various indications such as diabetes and weight management. This research and development progress may enhance market confidence in Amgen's future growth potential. The pharmaceutical industry is facing policy changes, and capital inflows are significant. Moderna rose 11.23%. Based on recent key news: On January 20, Moderna and Merck jointly disclosed that the mRNA tumor vaccine mRNA-4157 combined with Keytruda showed significant effects in reducing the risk of recurrence or death in melanoma patients during a five-year follow-up of phase two clinical trials, leading to a rise in stock price. Source: Reuters On January 21, analyst William Blair provided a positive evaluation of Moderna's five-year data update, believing it shows additional benefits in the postoperative environment, further enhancing market confidence in the company. Source: Benzinga On January 21, UBS analysts downgraded Moderna's rating to Neutral, with a target price of $34. Nevertheless, the market's positive response to its vaccine data still drove the stock price up. Source: UBS report on increasing competition in the vaccine industry, focusing on long-term data performance. Stocks ranked among the top in industry market capitalization Gilead Sciences rose 2.63%. Based on recent key news: On January 21, Jefferies analysts pointed out that the CARTITUDE-6 trial design of Legend has competitive implications for Gilead's anito-cel. The MRD negative endpoint of this trial may affect Gilead's market positioning, driving the stock price up. On January 20, Gilead Sciences was not included in the analysts' recommended list of the top five stocks. Although Gilead received a moderate buy rating, analysts believe that the other five stocks are more attractive, which may impact investor sentiment. No other significant news recently. Increasing competition in the biotechnology industry, focusing on policy changes